Open Access

Urinary pyridinoline cross-links as biomarkers of osteogenesis imperfecta

  • Uschi Lindert1,
  • Marius Kraenzlin2,
  • Ana Belinda Campos-Xavier3,
  • Matthias R. Baumgartner1,
  • Luisa Bonafé3,
  • Cecilia Giunta1Email author and
  • Marianne Rohrbach1
Orphanet Journal of Rare Diseases201510:104

https://doi.org/10.1186/s13023-015-0315-9

Received: 18 June 2015

Accepted: 30 July 2015

Published: 27 August 2015

Abstract

Osteogenesis imperfecta (OI) is a group of genetic heterogeneous connective tissue disorders characterized by increased bone fragility and susceptibility to fractures. Laboratory diagnosis relies on time-consuming and cost-intensive biochemical and molecular genetics analyses. Therefore, it is desirable to identify and establish new diagnostic markers for OI that are reliable, cost-effective and easily accessible. In our study we have identified the ratio of the urinary pyridinoline cross-links lysyl-pyridinoline and hydroxylysyl-pyridinoline as a promising, time- and cost-effective biomarker for osteogenesis imperfecta, that could be used furthermore to investigate cases of suspected non-accidental injury in infants.

Keywords

Osteogenesis imperfectaBiomarkerUrinary pyridinoline cross-linksLP/HP ratioCollagenMutationsNon-accidental injury

Dear Editor,

Osteogenesis imperfecta or “brittle bone disease” (OI) is a clinically and genetically heterogeneous disorder of bone matrix formation and remodelling, presenting with low bone mass, bone fragility and deformity, short stature, grey or blue sclera, and hearing loss. Its prevalence is about 1 in 15,000 to 20,000 births [1]. Approximately 90 % of OI cases are caused by dominant mutations in COL1A1 and COL1A2 resulting in quantitative and/or qualitative alterations of type I collagen, the major extracellular matrix component of bone and skin. A proportion of the remaining 10 % is due to either dominant or recessive mutations in several noncollagenous genes involved in the post-translational processing of procollagen I, in intracellular collagen transport, in osteoblast-specific signaling or in gene regulation [2].

Diagnosis of OI and identification of the disease-causing gene is important i) to end the patient’s quest for the disease causing his or her symptoms; ii) to allow for prenatal diagnosis, iii) to clarify cases of suspected “non-accidental injury” or “battered child syndrome”; iv) and to investigate the underlying pathomechanism in order to develop new therapeutic approaches. Establishing a specific diagnosis currently relies on biochemical analysis of collagens secreted by cultured fibroblast obtained by skin biopsies, and on molecular genetic analysis of the known OI related genes. The accessibility of modern genomic sequencing technologies has reduced the cost of molecular genetic testing, which was almost prohibitive in the past, due to the large number of genes, and exons per gene, to be sequenced. However, the interpretation of the molecular testing often requires biochemical investigations aimed to infer pathogenecity to the identified sequence variant if it is not yet reported on specialized mutation data bases such as the Database of Osteogenesis imperfecta variants at http://www.le.ac.uk/genetics/collagen/. Therefore, the cost remains a hurdle in OI diagnostics.

The urinary cross-links lysyl-pyridinoline (LP, or deoxypyridinoline DPD) and hydroxylysyl-pyridinoline (HP, or pyridinoline PYD) are established biochemical markers of osteoclastic bone resorption and collagen degradation. Pyridinolines are formed during fibril formation of type I and type II collagen in the extracellular matrix. Some lysyl- and hydroxylysyl-residues in distinct positions in the collagen triple-helix and in the telopeptides of the tropocollagen are oxidised by lysyl oxidase. Subsequently three of these residues are covalently linked thereby interconnecting tropocollagen molecules and stabilizing the collagen matrix. When bone collagen is degraded, pyridinolines remain as stable degradation products and are secreted with the urine. Depending on whether or not these lysyl residues had been hydroxylated prior to crosslinking, lysyl-pyridinoline (LP) or hydroxylysyl-pyridinoline (HP) is generated. Although LP and HP values in the urine vary substantially depending on age and time of sampling, their ratio is remarkably constant (LP/HP: 0.2 + 0.03) in healthy individuals at any age [3]. Furthermore, LP/HP ratios are proven diagnostic tools for genetic disorders of collagen metabolism such as the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) [4].

Since both dominant and recessive forms of OI lead to abnormal cross-linking chemistry in bone collagen [5], we hypothesize that the urinary LP/HP ratio may serve as a diagnostic biomarker for OI.

Methodology

The study was conducted according to the declaration of Helsinki, and approved by SwissEthics. To test whether the ratio of urinary pyridinolines LP/HP may be used as a biomarker for OI, we measured LP and HP cross-links by automated HPLC [3] in spot urines of 49 genetically defined OI patients. The study cohort included patients with mutations in the following genes: COL1A1 or COL1A2 (n = 24; including 6 patients aged 0.1-24 months), LEPRE1 (n = 8), CRTAP (n = 4), SP7/OSX (n = 1), BMP1/mTLD (n = 2), SERPINF1 (n = 2), the recurrent c.-14C > T in IFTM5 (n = 3), WNT1 (n = 1), PLOD2 (n = 1) and FKBP10 (n = 3), as well as heterozygous carriers for mutations in LEPRE1 (n = 2), CRTAP (n = 2) and SP7/OSX (n = 2).

Findings

LP/HP ratios are shown in Fig. 1. Compared to control LP/HP ratios (0.20 ± 0.03, n = 325) [3], we found (i) markedly decreased LP/HP ratios in OI patients with mutations in LEPRE1 (mean: 0.11), in CRTAP (mean: 0.106), in SP7/OSX (0.086) and in IFTM5 (mean: 0.095); (ii) moderately decreased ratios in patients with mutations in FKBP10 (mean: 0.128), in WNT1 (0.126), as well as in heterozygous carriers for a mutation in SP7/OSX (mean: 0.128); (iii) normal LP/HP ratios in patients with mutations in SERPINF1 (mean: 0.195), in BMP1/mTLD (mean: 0.226), and in heterozygous carriers for LEPRE1 (mean: 0.2) and CRTAP (mean: 0.172) mutations. In patients with COL1A1/COL1A2 mutations (mean: 0.184; n = 24), the LP/HP ratios were normal in 15/24, decreased in 8/24 and increased in 1/24. 6 out of 8 patients presenting with decreased LP/HP ratios were aged 0.1-2 years (normal values: 0.172 ± 0.02, age 1-12 months; 0.193 ± 0.03, age 1-3 years) [3].
Fig. 1

LP/HP ratios of OI patients, heterozygote carriers and controls [3]. OI patients with mutations in LEPRE1, CRTAP, SP7/OSX, FKBP10, WNT1 and IFTM5 show decreased LP/HP ratios compared to controls. Heterozygous carriers for a SP7/OSX mutation show slightly decreased ratios; carriers for LEPRE1 and CRTAP mutations show normal LP/HP ratios. OI patients with mutations in SERPINF1 or BMP1/mTLD have LP/HP ratios within the control range. In individuals with COL1A1/COL1A2 mutations LP/HP ratios were normal in 15/24, decreased in 8/24 and increased in 1/24. 6 out of 8 patients presenting with low LP/HP ratios were aged 0.1-2 years. Error bars indicates standard deviations (SD) or the highest measured value * (sample size n = 2)

Bisphosphonate treatment did not influence the ratio of total urinary pyridinoline cross-links (data not shown).

Conclusions

These results identify the urinary pyridinoline ratio LP/HP as a promising biomarker for some forms of OI. In particular, it has the potential to detect recessive forms of OI caused by mutations in the genes LEPRE1, CRTAP, FKBP10, WNT1 and SP7/OSX, and to discriminate between the dominant inherited forms caused by COL1A1/COL1A2 and IFTM5 mutations, therefore improving the efficacy of the final diagnosis and reducing the time and costs of laboratory investigations. Furthermore, the urinary LP/HP ratios might be helpful in investigating cases of suspected non-accidental injury in babies and infants aged 2 years and below.

More samples will be needed to establish urinary pyridinolines as a screening tool for OI diagnostics. Therefore, with this report we hope to attract more cases of OI with a known genetic defect in order to statistically validate our preliminary study.

Abbreviations

DPD: 

deoxypyridinoline

HP: 

hydroxylysyl-pyridinolines

LP: 

lysyl-pyridinolines

OI: 

osteogenesis imperfecta

PYD: 

pyridinoline

Declarations

Acknowledgements

We are most grateful to Profs. B. Steinmann, I. Kennerknecht, F. Rutsch, Ch. Netzer, VL. Ruiz-Perez, N. Elcioglu, M. Janner, B. Steiner, S. Temtami, M. Aglan, D. Sillence, EM. Abdalla, for contributing to this study with patient samples.

We thank Angelika Schwarze and Christine Plüss for expert technical assistance, and Dr. Sofie Symoens, Center for Medical Genetics Ghent, for communicating molecular genetic findings of some patients.

Funding sources

The work was supported by the Swiss National Science Foundation (SNF Grant Nr. 310030_138288) and the Gottfried und Julia Bangerter-Rhyner-Stiftung to CG and MR.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Metabolism, Connective Tissue Unit, University Children’s Hospital Zurich and Children’s Research Centre
(2)
Clinic for Endocrinology, Diabetology and Metabolism, University Hospital
(3)
Center for Molecular Diseases, Lausanne University Hospital

References

  1. Marini JC. Nelson textbook of pediatrics. Philadelphia: Saunders; 2004. p. 2336–38.Google Scholar
  2. Lindert U, Weis MA, Rai J, Seeliger F, Hausser I, Leeb T, et al. Molecular Consequences of Defective SERPINH1/HSP47 in the Dachshund Natural Model of Osteogenesis Imperfecta. J Biol Chem. 2015. doi:10.1074/jbc.M115.661025.PubMedGoogle Scholar
  3. Kraenzlin ME, Kraenzlin CA, Meier C, Giunta C, Steinmann B. Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem. 2008;54(9):1546–53. doi:10.1373/clinchem.2008.105262.View ArticlePubMedGoogle Scholar
  4. Steinmann B, Eyre DR, Shao P. Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI. Am J Hum Genet. 1995;57(6):1505–8.PubMed CentralPubMedGoogle Scholar
  5. Eyre DR, Weis MA. Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta. Calcif Tissue Int. 2013;93(4):338–47. doi:10.1007/s00223-013-9723-9.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Lindert et al. 2015

Advertisement